Celgene shares jumped as the biotech company posted top-and bottom-line beats and raised its earnings forecast for the year. Earnings of $1.44 a share was six cents better than expected. Revenue of $2.75 billion also beat estimates. The company relies heavily on its blood cancer drug Revlimid for the majority of its revenue. During the second-quarter the drug sales increased 18% from the same period last year. Celgene expects full-year earnings in the range of $5.70 to $5.75 a share on revenue of $11 billion.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
